RedHill Biopharma Ltd. files foreign-issuer reports that document its specialty biopharmaceutical business, ADS capital structure and corporate governance. Recent Form 6-K reports incorporate press releases and meeting materials covering Talicia commercialization, RHB-204, RHB-102 and opaganib development disclosures, and clinical or regulatory updates tied to gastrointestinal, infectious-disease and oncology programs.
The company’s SEC record also includes shareholder-meeting notices and voting results for restricted share unit grants and authorized share-capital changes, as well as Nasdaq listing-compliance communications for its American depositary shares. Incorporation-by-reference language links these current reports to Form S-8 equity compensation registrations and Form F-3 shelf registration statements, reflecting recurring disclosure topics around financing capacity, equity plans, governance and material events.
RedHill Biopharma Ltd., a foreign private issuer based in Tel Aviv, reports that at its adjourned Annual General Meeting of Shareholders held on August 7, 2026, all resolutions proposed to shareholders were duly approved. This confirms shareholder support for the full slate of items presented at that meeting.
The company also states that this report is incorporated by reference into multiple existing Registration Statements on Form S-8 and Form F-3, linking the AGM outcomes and related disclosures into its broader U.S. securities registration framework.
RedHill Biopharma Ltd. reports that its Annual General Meeting of Shareholders scheduled for August 6, 2026 was adjourned due to a lack of required legal quorum. Under its Amended and Restated Articles of Association, the meeting will reconvene on August 7, 2026 at 3:00 p.m. Israel time at the company’s Tel Aviv offices.
The report is also incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, meaning the disclosed information is now legally part of those previously filed offerings documentation.
RedHill Biopharma outlines ongoing development of its investigational antiviral opaganib for Ebola virus disease as the Bundibugyo ebolavirus outbreak grows to 3,221 confirmed cases and 1,407 deaths as of July 28, 2026. Next-step planning and potential partnership discussions involve the African Medicines Agency’s Emergency Task Force, Uganda’s Ministry of Health, Mbarara University of Science and Technology, and the Democratic Republic of Congo’s Scientific Advisory Committee.
The company highlights opaganib’s oral, host-directed mechanism and safety experience in more than 470 participants. Phase 3 severe COVID-19 data showed a 70.2% mortality reduction when opaganib was added to remdesivir, with faster viral RNA clearance and no additional safety signals, alongside USAMRIID-funded preclinical Ebola studies and prior BARDA selection of opaganib as a potential medical countermeasure. Opaganib remains an investigational drug and is not approved or commercially available.
RedHill Biopharma Ltd. is registering up to 26,228,573 American Depositary Shares (ADSs) for resale by existing holders. These ADSs are issuable upon exercise of pre-funded, Series A-1, Series A-2 and placement agent warrants from a June 2026 private placement, with each ADS representing 10,000 ordinary shares.
The company will not receive proceeds from resale of the ADSs. It would receive up to approximately $13.8 million in gross proceeds only if all warrants are exercised for cash, which it currently plans to use for working capital, research and development and general corporate purposes. ADSs outstanding were 6,080,920 at the time of the offering summary.
RedHill describes significant potential dilution from options, RSUs and warrants and details past and current challenges meeting Nasdaq listing standards, including the $1.00 minimum bid price, stockholders’ equity requirements and a proposed $5 million market value threshold. Its independent auditors have previously highlighted substantial doubt about the company’s ability to continue as a going concern.
RedHill Biopharma Ltd. insider Raday Gilead, Chief Operating Officer, reported compensation-related equity activity. A trustee sold 1,413 American Depositary Shares (ADS), each representing 10,000 ordinary shares, solely to satisfy tax withholding obligations arising from the vesting of 4,228 restricted share units granted between July 2023 and January 2026. The ADS were sold at $0.6973 per ADS, equivalent to $0.00006973 per ordinary share, under a sell-to-cover policy and the filing states this did not represent a discretionary trade by Gilead. The report also shows a derivative exercise/conversion related to ADS into ordinary shares, with Gilead continuing to hold a substantial direct position after these transactions.
RedHill Biopharma Ltd. registers up to 26,228,573 ADSs (each ADS represents 10,000 ordinary shares) for resale by selling shareholders under a Form F-3 registration statement dated July 2, 2026. The ADSs were issued in connection with warrants from a June 2026 private placement.
The selling shareholders will receive all proceeds from resales; the Company will not receive proceeds from resale transactions but would receive exercise prices if the related warrants are exercised for cash, which would yield potential gross proceeds of approximately $13.8 million if exercised in full. The ADSs trade on Nasdaq under the symbol RDHL; the last reported sale price was $0.83 per ADS on July 1, 2026.
RedHill Biopharma Ltd. has rescheduled its annual general meeting of shareholders to August 6, 2026, and issued updated proxy materials. Shareholders will vote on re-appointing Kesselman & Kesselman (PwC Israel) as auditors for 2026, re-electing directors Rick D. Scruggs and Dr. Shmuel Cabilly, and approving the continued engagement of co-founder Dror Ben-Asher as both Chairman of the Board and Chief Executive Officer for a further three-year term beginning August 6, 2026. They will also vote on amending the Articles of Association to eliminate the NIS 0.01 par value of the company’s shares, converting them into no-par-value shares without changing authorized capital. Holders of record of ADSs as of July 2, 2026, representing 60,809,201,000 ordinary shares, are entitled to vote, with a 25% quorum requirement and a special majority condition applying to the CEO/Chairman combination proposal.
RedHill Biopharma Ltd. filed a Form 6-K to report that it has increased the maximum aggregate offering amount of American Depositary Shares that may be issued and sold under its existing at-the-market equity program with H.C. Wainwright & Co., LLC.
Each American Depositary Share represents ten thousand of RedHill’s ordinary shares. The filing also attaches updated legal opinions and consents as exhibits and incorporates this report by reference into multiple existing Form S-8 and Form F-3 registration statements.
RedHill Biopharma Ltd. amends its Form F-3 prospectus supplement to increase the amount of American Depositary Shares available under its At The Market sales agreement by up to $2,128,000. The supplement states this amount is in addition to $49,690 of ADSs previously sold under the same agreement.
The supplement cites General Instruction I.B.5 of Form F-3 and reports the aggregate market value of Ordinary Shares held by non-affiliates as $6,534,464 based on 59,949,221,000 Ordinary Shares held by non-affiliates (represented by 5,994,922 ADSs and a per-ADS price of $1.09 as of April 30, 2026. The ADSs trade on Nasdaq under the symbol RDHL; the last reported sale price on June 26, 2026 was $0.8786 per ADS.